cology, Gazi University Faculty of Medicine. Those patients who did not have clinically localized disease, who had undergone radical prostatectomy prior to radiation therapy, who had received a total dose <66 Gy, who had been treated with palliative intent or who had diagnostic biopsies performed at other institutions were excluded. As a consequence, 41 patients who had received radiation therapy (with or without hormonal therapy) with curative intent for clinically localized disease were included in this study. Oral informed consent was obtained from patients who participated in this study. All patients had adenocarcinomas. Their medical records were reviewed to assess disease and treatment characteristics and the presence or absence of BF. The end of the follow-up period was March 2009.
Clinical T stage was T1c to T2a in 22 patients (54%) and ≥T2b in 19 patients (46%). At the time of diagnosis, the mean PSA level was 17.9 ng/mL (2-66 ng/mL) and the PSA levels of 21 patients (51%) were ≤10 ng/mL. Gleason scores reported from transrectal biopsies were ≤6 in 26 patients (63%) and >6 in 15 patients (37%) ( Table 1) . According to the risk classification scheme proposed by D'Amico et al. (8) , 18 patients (44%) were classified into the low-risk group, eight patients (19.5%) were classified into the intermediate-risk group and 15 patients (36.5%) were classified into the high-risk group.
Treatment technique
All patients were treated with high energy linear accelerators (10 MV and/or 15 MV photon beams) (Saturn 41, General Electric, Buc, France). Patients were generally treated with the four-field box technique. Planning treatment volume was the prostate and the vesicles with margins. Regional nodes were prophylactically included for high risk patients (with PSA >20 ng/mL and/or Gleason score >7). The majority of patients were treated to 70 Gy with daily fractions of 2 Gy. Ten patients (24%) were treated with radiation therapy alone while 31 patients (76%) received either short-term (17 patients) or long-term (14 patients) hormonal therapy (Table 1 ). All patients had PSA testing at regular three-monthly intervals during follow-up.
Assessment of VEGF expression
Tissue sections of 4 μm were cut from previously prepared representative formalin-fixed and paraffin-embedded blocks. Sections were deparaffinized in xylene and rehydrated. Immunoperoxidase staining was performed using the streptavidin-biotin peroxidase method. The sections were treated with 0.3% H 2 O 2 in order to suppress endogenous peroxidase activity. Sections were pretreated with ethylenediaminetetraacetic acid (EDTA) to retrieve antigen expression and incubated with anti-VEGF monoclonal antibody (1:50 diluted, clone VG1, NeoMarkers). As a chromogen for color development, 3-amino-9-ethylcarbazole substrate (AEC; LabVision, NeoMarkers) was used. The slides were counterstained with hematoxylin, dehydrated and mounted. Sections of angiosarcoma were used as the positive control. For the negative control, phosphate buffered saline replaced the primary antibody. Stained slides were examined to identify VEGF immunoreactivity. VEGF expression was assessed using a semiquantitative scoring method that was blinded to patient outcome. The percentage of positively stained glands (none=0; less than 1%=1, 1-10%=2; 11-33%=3; 34 -67%=4; and more than 67%=5) and the staining intensity (none= 0; weak= 1; moderate= 2; strong= 3) were evaluated. The percentage scores and the intensity scores were added to give a final immunoreactivity score (IRS) that ranged from 0 to 8. For the purpose of statistical analysis, IRS was classified as low (0 to 4) or high (5 to 8) (9) .
Statistical analysis
For the purpose of statistical analysis (due to the limited number of patients), the intermediate-risk group and the high-risk group were merged to define low-risk patients (clinical T stage T1c to T2a, initial PSA ≤10 ng/mL and Gleason score ≤6) and high-risk patients (clinical T stage ≥T2b and/or initial PSA >10 ng/mL and/or Gleason score ≥7). BF was defined as rising PSA levels in three consecutive measurements following radiation therapy. Overall survival (OS) was calculated from the final day of radiation therapy to death. Patients who were alive were censored at their last follow-up for OS. Biochemical failure-free survival (BFFS) was calculated from the final day of radiation therapy to the time when BF was established. Patients dying without BF were classified as censored observations at the time of death and all other patients were censored at their last follow-up for the BFFS.
Statistical analysis was performed using SPSS for Windows version 17.0 (SPSS Inc., 2008, Chicago, IL, USA). Differences between patient groups were evaluated using the chi-square test. Survival estimations were performed using the method of Kaplan and Meier, univariate analysis using the log-rank test and log-rank test for linear trend. Statistical significance was considered when the p-value was less than or equal to 0.05.
RESULTS
The median age was 71 years (range, 58-82 years). The median radiation therapy dose was 70 Gy, ranging from 66 to 74 Gy. Follow-up ranged from 3 to 12.2 years (median, 5.4 years).
VEGF expression
VEGF expression was evaluated as low in 24 patients (59%) and high in 17 patients (41%) ( Table 1 ). Higher VEGF expression was observed in 16 out of 22 patients with a low clinical T stage as compared to in 8 out of 19 patients with a high clinical T stage, the difference being statistically significant (p=0.05, χ 2 =3.94). VEGF was overexpressed in 7 out of 21 patients with a low initial PSA level as compared to 10 out of 20 patients with a high initial PSA level; this difference was not statistically significant (p>0.05, χ 2 =1.17). On the contrary, higher VEGF expression was observed in 6 out of 26 patients with a low Gleason score as compared to in 11 out of 15 patients with a high Gleason score; this difference was statistically significant (p=0.02, χ 2 =9.89). However, when defined risk groups based on the initial PSA level and Gleason score were analyzed, VEGF was overexpressed in 4 out of 18 patients in the low risk group as compared to in 13 out of 23 patients in the high risk group; this difference was statistically significant (p=0.03, χ 2 =4.89).
Biochemical failure
For the entire group, BF was observed in 9 patients (22%). BF was observed in none of the 22 patients with a low clinical T stage as compared to in 9 out of 19 patients with a high clinical T stage; this difference was statistically significant (p<0.001, χ 2 =13.35). BF was observed in 3 out of 21 patients with a low initial PSA level as compared to 6 out of 20 patients with a high initial PSA level; this difference was not statistically significant (p>0.05, χ 2 =1.48). On the contrary, BF was observed in 1 out of 26 patients with a low Gleason score as compared to in 8 out of 15 patients with a high Gleason score; this difference was statistically significant (p<0.001, χ 2 =13.59). However, when defined risk groups based on the initial PSA level and Gleason score were analyzed, BF was reported in none of the 18 patients in the low risk group as compared to in 9 out of 23 patients in the high risk group; this difference was statistically significant (p=0.03, χ 2 =9.02). BF was observed in 2 out of 24 patients with low VEGF expression as compared to in 7 out of 17 patients with high VEGF expression; this difference was statistically significant (p=0.01, χ 2 =6.27). In the univariate analysis, having a higher clinical T stage (p<0.001), having a higher Gleason score (p<0.01), being in the high risk group (p=0.03) and having higher VEGF expression (p=0.01) were predictors of BF after definitive radiation therapy ( Table 2) .
Biochemical failure free survival
The biochemical failure free survival (BFFS) rate at 5 years was 76% for the entire group of patients. The BFFS rate at 5 years was 100% vs. 46% when patients were grouped according to clinical T stage (p<0.001), 86% vs. 63% when patients were grouped according to the initial PSA level (p=0.17), 96% vs. 42% when patients were grouped according to the Gleason score (p<0.01) and 100% vs. 54% when patients were grouped according to risk groups (p=0.001). The BFFS rate at 5 years tended to be different (91% vs. 53%) when pa- Figure 1 a-e).
DISCUSSION
Radiation therapy (with or without hormonal therapy) is the primary treatment option for patients with clinically localized prostate cancer. Well-documented prognostic factors such as Tstage, Gleason score and PSA indicate the natural history of the disease and determine the recurrence risk (10, 11) . However, it might be challenging to identify patients who are at increased risk for recurrence. Therefore, cellular and molecular biological markers that might better predict possible radiation therapy resistance and outcome are needed to make treatment decisions.
Folkman (12) showed that angiogenesis is a necessary component of solid tumor growth. VEGF is a key regulator of angiogenesis and is involved in tumor angiogenesis by increasing vascular permeability, endothelial cell growth, proliferation, migration and differentiation (13) . VEGF overexpression takes place through the adaptation of the tumor microenvironment to hypoxia (14) . Tumor hypoxia might be an explanation for treatment failure following radiation therapy. Hypoxia has been associated with poor prognosis in a variety of cancers including the stomach, the esophagus, the breast, the colorectum, the head and neck and the cervix (15-20, 3, 4) .
Some studies have reported a relationship between VEGF expression and poorer tumor control together with diminished survival following radiation therapy in different cancers such as the rectum, the breast and the cervix. Peng et al. (21) reported that VEGF expression may predict distant metastases and disease-free survival in stage III rectal cancer following preoperative radiation therapy and also suggested that inhibition of VEGF in combination with radiation therapy may improve outcome. Linderholm et al. (18) showed that high VEGF expression can point to a resistant phenotype for node-negative breast cancer patients treated with only locoregional radiation therapy, or indicate early metastases which requires treatment. Another study evaluating the relationship between VEGF expression and radiation therapy outcome in advanced cervical cancer reported that expression of VEGF, as assessed by IHC analysis, is a highly significant prognostic factor for survival and metastasis-free survival but not for local control (22) .
For clinically localized prostate cancer, the role of tumor hypoxia and angiogenesis has recently come under the spotlight. The presence of hypoxic regions in prostate cancer has been documented in the literature, both through the use of physical measurements (such as the pO 2 probes) and the identification of specific biomarkers. In their study on patients with localized prostate cancer, Movsas et al. (2) reported that tumor hypoxia was associated with poor prognosis, since low pO 2 levels (measured by an Eppendorf microelectrode) in the prostate were associated with higher BF assessed by PSA. Furthermore, Cvetkovic et al. (9) demonstrated a significant correlation between preoperative prostate hypoxia level (assessed by an Eppendorf oxygen microelectrode) and the percentage of cells staining positive for VEGF. One of the earliest VEGF expression studies showed that the majority of prostatic carcinoma specimens exhibited cytoplasmic staining for VEGF, with VEGF expression increasing with dedifferentiation of the tumor (23). Peyromaure et al. (24) studied VEGF-A expression in prostate cancer patients undergoing radical prostatectomy. They found higher expression of VEGF in men who developed bone metastases as compared to those who remained free of recurrence following surgery. As a result, they suggested that VEGF expression could be a factor associated with cancer progression following radical prostatectomy.
In the present study, higher VEGF expression was observed in 27% of patients with a low clinical T stage as compared to 58% of patients with a high clinical T stage. VEGF was overexpressed in 33% of patients with a low initial PSA level as compared to 50% of patients with a high initial PSA level. On the contrary, higher VEGF expression was observed in 23% of patients with a low Gleason score as compared to 73% of patients with a high Gleason score. Furthermore, BF was observed in 8% of patients with a low VEGF expression as compared to of 41% of patients with a high VEGF expression. The BFFS rate at 5 years was 91% for patients with a low VEGF expression versus 53% for patients with a high VEGF expression. There have only been a few studies that differentiated patients with radiation therapy sensitive prostate cancer from those with a poor outcome. In agreement with the results of our study, Green et al. (25) reported that higher tumor VEGF expression on pretreatment biopsies was correlated with an adverse outcome following radiation therapy. They found that VEGF was the only significant prognostic factor in terms of disease-specific survival (p=0.035). They also reported a statistically significant association between high VEGF expression and increased Gleason score (p=0.02), but failed to observe any correlation between VEGF expression and BF, in contrast with the results of our study. Vergis et al. (7) evaluated intrinsic markers of hypoxia and angiogenesis (HIF-1α, osteopontin and VEGF) in relation to the outcome of localized prostate cancer patients who were treated with curative intent, either using radical radiation therapy or radical prostatectomy. They reported that increased expression of VEGF was a significant predictor of worse freedom from BF for patients treated with radical radiation therapy as well as those treated with radical prostatectomy, in agreement with the results of our study.
In an attempt to define patients with clinically localized prostate cancer who are sensitive to standard treatment modalities such as surgery, radiation therapy and hormonal therapy, it is clear that cellular and/or molecular biological markers are The relationship between VEGF and prostate cancer has been extensively studied. However, only a small number of studies evaluated the effects of VEGF expression on outcome, regardless of the treatment modality used. Furthermore, these studies were underpowered in terms of both the number of patients involved and the extent of follow-up. Vergis et al. (7) speculated that the associations between clinical outcome and staining for VEGF (as well as other markers of hypoxia such as HIF-1α and osteopontin) are not sufficient to conclude that tumor hypoxia and angiogenesis adversely affect treatment efficacy and that these markers constitute therapeutic targets. Furthermore, they suggested that "VEGF might only serve as one of the markers pointing to an aggressive tumor type". It is for the aggressive counterparts of prostate cancer that anti-VEGF treatments could prove beneficial. Recent preclinical studies have shown that anti-VEGF agents can "normalize" tumor associated blood vessels, which is a mechanism of radiosensitization (26, 27) . Based on the results of these preclinical studies, Vuky et al. (28) designed a phase II study examining the effect of an anti-VEGF agent concurrently with radiation therapy for high risk prostate cancer. They reported that the anti-VEGF agent did not appear to exacerbate the acute effects of radiation therapy; however, the impact on outcome remained unclear. Therefore, as a conclusion, further investigations that aimed to associate VEGF as well as other markers of angiogenesis and hypoxia with treatment outcome are required for patients with clinically localized prostate cancer.
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